8-K: Immunic Appoints Jason Tardio as COO and President, Promotes Werner Gladdines to Chief Development Officer

Immunic, Inc. has appointed Jason Tardio as Chief Operating Officer and President and promoted Werner Gladdines to Chief Development Officer to strengthen its leadership team as it prepares for potential commercialization of its lead drug candidate.

Summary

• Immunic, Inc. has appointed Jason Tardio as Chief Operating Officer and President, effective July 12, 2024.
• Mr. Tardio will be responsible for preparing the company for the potential launch of vidofludimus calcium (IMU-838).
• He will also collaborate with the Chief Business Officer to explore partnership opportunities.
• Mr. Tardio's compensation includes a $500,000 annual base salary, a potential 40% bonus, and a $120,000 signing bonus.
• He will also receive stock options for 500,000 shares, vesting over four years.
• Werner Gladdines has been promoted to Chief Development Officer, overseeing clinical operations.
• Mr. Gladdines previously served as Vice President, Program Management & Clinical Development Operations.
• The company is preparing for the read-out of its phase 2 CALLIPER trial in progressive MS expected in April 2025.
• The completion of its twin phase 3 ENSURE trials in relapsing MS is expected in the second quarter and the second half of 2026, respectively.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the appointment of experienced leadership and the progress of clinical trials. The company is clearly positioning itself for future growth and commercial success.

Positives

• The appointment of Jason Tardio brings extensive experience in commercializing multiple sclerosis drugs from Novartis and Biogen.
• Mr. Tardio's experience includes successful out-licensing transactions.
• Werner Gladdines' promotion recognizes his significant contributions to the company's clinical operations.
• The company is actively preparing for the potential launch of vidofludimus calcium.
• The company has a clear timeline for upcoming clinical trial readouts.

Risks

• The company's success is dependent on the outcome of clinical trials.
• There are risks associated with the drug development and regulatory approval process.
• The company faces competition from other pharmaceutical companies.
• The company's future cash utilization and reserves are subject to uncertainty.
• The COVID-19 pandemic, increasing inflation, and geopolitical conflicts could impact clinical trials.

Future Outlook

The company is focused on preparing for the potential launch of vidofludimus calcium and advancing its clinical programs, with key trial readouts expected in 2025 and 2026.

Management Comments

• Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, stated that Jason Tardio's experience is invaluable as they approach the completion of the vidofludimus calcium phase 3 ENSURE program.
• Mr. Tardio stated he is enthusiastic about bringing a much-needed oral treatment option to patients with relapsing and progressive forms of MS.
• Mr. Tardio believes vidofludimus calcium has the potential to meaningfully enhance therapeutic options and tap enormous markets.

Industry Context

This announcement reflects a strategic move by Immunic to strengthen its leadership team with experienced executives as it progresses towards potential commercialization of its lead drug candidate in the competitive multiple sclerosis market.

Comparison to Industry Standards

• Jason Tardio's previous roles at Novartis and Biogen, where he launched successful MS drugs like MAYZENT, AVONEX, and PLEGRIDY, demonstrate his experience in the industry.
• His experience in out-licensing transactions is also valuable, as many biotech companies rely on partnerships for commercialization.
• The promotion of Werner Gladdines to Chief Development Officer is a common practice in biotech companies to recognize and leverage internal talent.

Management Changes

Stakeholder Impact

• Shareholders may view the new appointments positively, as they bring experience and expertise to the company.
• Employees may be motivated by the company's progress and the addition of experienced leaders.
• Patients may benefit from the potential launch of new treatment options for multiple sclerosis.
• Partners may be interested in collaborating with the company due to its progress and leadership.

Next Steps

• The company will prepare for the potential launch of vidofludimus calcium.
• The company will continue to advance its clinical programs.
• The company will prepare for the read-out of the phase 2 CALLIPER trial in April 2025.
• The company will complete the twin phase 3 ENSURE trials in 2026.

Key Dates

Keywords

Immunic, Jason Tardio, Werner Gladdines, Chief Operating Officer, Chief Development Officer, vidofludimus calcium, IMU-838, multiple sclerosis, clinical trials, biopharmaceutical, commercialization, partnership